OKYO Pharma (OKYO) Stock Price, News, Quotes-Moomoo

$OKYO Pharma (OKYO.US)$
OKYO Pharma Granted U.S. Patent Covering OK-101's Potential for Treating Symptoms of Dry Eye Disease
LONDON and NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated ...

Trytosaveabit

Aug 27 06:04

News

$OKYO Pharma (OKYO.US)$ OKYO Pharma Secures US Patent Covering OK-101's Potential To Treat Symptoms Of Dry Eye Disease
Benzinga· 2 mins ago

Trytosaveabit

Aug 23 06:23

This may be why? New filing a bit ago

$OKYO Pharma (OKYO.US)$ announced today that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 50,000 of the Company’s ordinary shares on NASDAQ at a price of US$1.05 per share. This brings the total shareholding of Mr Cerrone to 9,721,570 shares which is 28.73% of issued share capital.

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

OKYO OKYO Pharma

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target